The state of Georgia currently has 23 active clinical trials seeking participants for Asthma research studies. These trials are conducted in various cities, including Atlanta, Augusta, Decatur and Savannah.
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
Recruiting
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
03/04/2025
Locations: Research Site, Atlanta, Georgia +1 locations
Conditions: Asthma
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
Recruiting
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: GSK Investigational Site, Columbus, Georgia
Conditions: Asthma
A Study to Assess the Effect of Dexpramipexole in Participants With Severe Eosinophilic Asthma.
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/24/2025
Locations: Research Site 20001-075, Augusta, Georgia +2 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
02/24/2025
Locations: Research Site US-30001-452, Dunwoody, Georgia +2 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/16/2025
Locations: Appalachian Clinical Research- Site Number : 8400050, Calhoun, Georgia
Conditions: Asthma
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/12/2025
Locations: Research Site, Decatur, Georgia +1 locations
Conditions: Asthma
Asthma Navigator Intervention to Improve Health Equity in Children
Recruiting
The goal of this study is to improve health equity in children aged 5-16.9 years admitted to the PICU for asthma. The objectives are: * To identify the factors related to differential experiences of asthma self-management * To pilot the effectiveness of an individualized asthma navigator intervention at PICU discharge.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
01/22/2025
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Asthma in Children
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Recruiting
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/19/2024
Locations: Research Site, Columbus, Georgia +1 locations
Conditions: Asthma
Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma
Recruiting
This study is a two strata, dose escalation Phase I clinical trial designed to assess the safety and determine the maximal tolerated dose (MTD) of allogenic cord tissue derived MSCs (cMSCs, stratum 1) and allogeneic, interferon-γ primed bone marrow MSCs (γMSCs, stratum 2). Each stratum is designed to independently accrue 3 children at a dose level 1 of 2x106 cells/kg and 6 children at dose level 2 of 10x106 cells/kg, resulting in 9 children in each stratum. The primary objectives are to determin... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
09/10/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Asthma
Symptom Clusters in Children With Exacerbation-prone Asthma
Recruiting
Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks. The study visit 2 weeks after the injection will assess the response to the study medication, while the remaining study visits will examine the temporal stability of the symptom clusters.
Gender:
ALL
Ages:
Between 6 years and 21 years
Trial Updated:
07/15/2024
Locations: Children's Healthcare of Altanta, Atlanta, Georgia +1 locations
Conditions: Asthma in Children
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
Recruiting
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
05/24/2024
Locations: GSK Investigational Site, Savannah, Georgia
Conditions: Asthma